Civica collaborates with Ypsomed for pen production

Civica, an insulin manufacturer based in Lehi in the US state of Utah, is seeking a partner for the marketing of biosimilar insulins. According to a press release, Civica has entered into an agreement for the production of new pens with Swiss medical technology company Ypsomed AG. The pens manufactured at sites in Switzerland and Germany will be able to inject glargine, lispro, and aspart insulins. These are equivalent to the brands Lantus, Humalog, and NovoLog, respectively, but Civica will offer these drugs at a significantly lower price than the branded versions on the market today. In its press release, the American company explains that it plans to make insulin “affordable to everyone”.

Ned McCoy, President and CEO of Civica, commented: “As a renowned injection device specialist with over 35 years’ experience, Ypsomed will help Civica make self-administered care more affordable for Americans living with diabetes.” Civica is also creating its own new production site in Petersburg, Virginia. eb